Silencing MAO-A has growth-suppressing effects in mouse prostate tumors, including the CRPC phenotype, while the anti-tumoral effect of enzalutamide, darolutamide, and apalutamide was greatly enhanced by MAO-A genetic or pharmacological inactivation in both androgen-dependent and CRPC cells [49]. The gene discussed is MAOA; the disease is prostate neoplasm.